ARVN News and Press, Arvinas Inc. From 02/01/21

On January 13, ESSA announced a collaboration agreement with Janssen to evaluate ESSA's EPI-7386 in combo with Janssen's apalutamide and in combo with abiraterone acetate plus prednisone in patients with mCRPC. EPI-7386 is a novel approach to treat prostate cancer by targeting the N-t...

2020 was a year of immense adversity and contrast, as stocks bounced back sharply from a pandemic-induced bear market. Biotechs play a pivotal role in managing down the pandemic as vaccine production ramps higher. January to provide further insights on multiple additional vaccine tria...

Arvinas is a leader in protein degrader technology. They have shown first outstanding results in phase 1 trials in breast and prostate cancer. The price is high, but given their potential, a pilot and then accumulation at dips is my strategy. For further details see: Arv...

NEW HAVEN, Conn., Dec. 28, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC ® Discovery Engine, today announced that the underwriters of its previously ...

C4 Therapeutics, along with a host of others, is developing therapeutics in the cutting edge field of protein degraders. Blockbuster drugs like Revlimid and Pomalyst are now known to be protein degraders. In preclinical trials, C4's molecule has done better than Pomalyst in MM xen...

Listen on the go! A daily podcast of Wall Street Breakfast's Alpha Talks will be available this morning on Seeking Alpha, iTunes, Stitcher and Spotify. Stocks snapped their three-day advance with small losses Friday in volatile quadruple witching trading, as progress stalled on a COVID financ...

Arvinas (ARVN) has priced its public offering of 5,714,286 common shares at $70.00/share.Underwriters' over-allotment is an additional 857,142 shares. Closing date is December 18.Yesterday's close was $74.25.Previously: Arvinas proposes $250M equity offering (Dec. 14) For further details se...

NEW HAVEN, Conn., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation using its PROTAC ® Discovery Engine, today announced the pricing of an underwritten public of...

Notwithstanding the $250M worth equity offering, Arvinas (ARVN) extends the near two-fold gain posted yesterday, rising another +25.9% in value as Roth and Guggenheim upgraded their price targets.In an announcement yesterday, the company highlighted the promising clin...

Looking To Add Biotech Stocks To Your Watchlist? 3 Making Moves This Week It has clearly been the year of biotech stocks in the stock market. Investors and biotech companies alike will likely agree. Most of the top biotech stocks have seen massive rallies throughout this yea...